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Abstract 
 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of inflammatory 
demyelination, a pathological event common to multiple sclerosis (MS). During CNS 
inflammation there are alterations in the extracellular matrix (ECM). A Disintegrin and 
Metalloproteinase with Thrombospondin motifs (ADAMTS) -1, -4 and -5 are proteases 
present in the CNS, which are able to cleave the aggregating chondroitin sulphate 
proteoglycans, aggrecan, phosphacan, neurocan and brevican. It is therefore important to 
investigate changes in their expression in different stages of EAE induction. We have 
investigated expression of ADAMTS-1, -4, -5 and Tissue inhibitor of metalloproteinase 
(TIMP) -3, by real-time RT-PCR. We have also examined protein expression of ADAMTS-1, 
-4 and -5 by western blotting and immunocytochemistry in spinal cord from animals at 
different stages of disease progression. Our study demonstrated a decrease in ADAMTS-4 
mRNA and protein expression. TIMP-3 was decreased at the mRNA level although protein 
levels were increased in diseased animals compared to controls. Our study identifies changes 
in ADAMTS expression during the course of CNS inflammation which may contribute to 
ECM degradation and disease progression.  
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Introduction 
The  extracellular matrix (ECM) of the central nervous system (CNS) has both structural and 
functional roles including anchorage of molecules such as integrins and growth factors. The 
CNS ECM shares many components found in the ECM of other tissues but differs somewhat 
in its relatively low collagen and fibronectin content and larger amounts of 
glycosaminoglycans, either bound to proteins in the form of proteoglycans or unbound as 
hyaluronan. Proteoglycans of the brain include the chondroitin sulphate proteoglycans 
(CSPGs) aggrecan, brevican, neurocan, phosphacan, appican and versican [1-5]. These 
molecules are important to brain structure through maintenance of the correct hydrodynamics 
and in their interactions with other ECM components. They also contribute to disease 
processes and their synthesis is modulated by injury. As a group they are known to inhibit 
neurite outgrowth and axonal regeneration and promote neural cell death [5-9]. However 
enzymic removal of chondroitin sulphate promotes axonal regeneration [10]. Maintenance of 
the appropriate quantity and location of CNS CSPGs is thus likely to be of major importance 
to the correct functioning of the brain and may also influence the balance between neuronal 
death and survival. 
 
Experimental autoimmune encephalomyelitis (EAE) is a model of neuroinflammation with 
clinical and histopathological similarities to multiple sclerosis (MS) [11]. Extracellular 
proteolytic enzymes are implicated in the pathology of both MS and EAE and in particular the 
role of matrix metalloproteinases (MMPs) is well established [12-16]. The roles of MMPs in 
neuroinflammation include disruption of the blood-brain barrier by breakdown of the ECM 
around blood vessels and the use of MMP inhibitors has shown reduced clinical severity of 
EAE [16].  More recently, some of the ADAM metalloproteinases have been shown to have 
an important role in CNS inflammation [17]. It is therefore of importance to determine 
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whether the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) 
group of metalloproteinases [18,19], known to be expressed in the CNS [20-23], are 
modulated in CNS inflammatory conditions such as EAE and MS.  
 
The ADAMTSs are a distinct group of phylogenetically related proteins in Family M12 of 
Clan MA in the Merops database (http://merops.sanger.ac.uk/) [24] and are related to the 
ADAMs and matrix metalloproteinases. A phylogenetic subgroup of the ADAMTS enzymes 
comprising ADAMTS-1, -4, (EC 3.4.24.82) -5, -8, -9, and -15 possess proteoglycanase and 
anti-angiogenic activities [25]. ADAMTS-1, -4, -5, -8 [26] and -9 possess aggrecanase 
activity and have been implicated in cartilage degradation [27],[28]. Molecular modeling has 
suggested that ADAMTS-15 possesses the same or similar activity [29]. It is known that 
ADAMTS-1, -4 and -9 are capable of cleaving versican [28], [30], and brevican is cleaved by 
ADAMTS-4 [31]. The ADAMTS proteoglycanases are inhibited by tissue inhibitor of 
metalloproteinases (TIMP)-3 [32] which, like the ADAMTSs, is sequestered in the ECM via 
interactions with sulphated glycosaminoglycans [33-35].  
 
To our knowledge this is the first study of ADAMTS expression in EAE. We have 
investigated the expression of the proteoglycanases ADAMTS-1, -4, and -5, the original 
ADAMTSs categorized as aggrecanases and for which antibodies were available, as well as 
their inhibitor TIMP-3, in animals at different stages of EAE. We demonstrate differential  
expression of  proteases and ECM components in an inflammatory environment in vivo. 
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Materials and Methods 
Spinal cord tissue 
Spinal cord tissue from Lewis rats following EAE induction by immunisation with spinal cord 
homogenate plus adjuvant was kindly provided by Dr T Smith, Eisai Research Laboratories, 
London, UK. Clinical disability was scored: 0, no detectable change in muscle tone and motor 
behaviour; 1, flaccid tail; 2, impairment of righting reflex and/or loss of muscle tone in 
hindlimbs; 3, complete hindlimb paralysis; 4, paraplegia; and 5, death [36]. Tissue was snap 
frozen in liquid nitrogen cooled isopentane and included: 5 naïve controls, 4 animals which 
were pre-disease (sacrificed on day 10 post-immunisation, prior to the onset of disease 
symptoms, disability score of 0), 5 animals at the peak of disease (sacrificed on day 12 post-
immunisation, disability score of 3-3.25) and 6 recovered animals (sacrificed 4 days after 
their disability score had returned to 0).  
 
RNA and protein extraction 
  Spinal cord white matter was excised and homogenised in Tri-reagent (Sigma, UK), 
followed by vortex mixing and centrifugation at 12000 x g for 15 minutes at 4°C to remove 
lipids. The supernatant was then transferred to a clean microfuge tubes and the RNA and 
protein were extracted following the manufacturer’s instructions. Protein was stored at 4°C 
and RNA at -80°C prior to use. 
 
Real-time (q) RT-PCR 
RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen, Paisley, 
UK) and the resulting cDNA was used as a template for qRT-PCR using the ABI PRISM 
7900HT sequence detection system  and 2xSYBR Green mastermix (Applied Biosystems, 
Warrington, UK) for primers designed using Primer Express software (Applied Biosystems). 
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Primers were synthesised by MWG Biotech (Ebbersberg, Germany). In order to preclude the 
amplification of nuclear DNA, all primers crossed an exon-exon boundary. Primer sequences 
and accession numbers are shown in Table 1. Expression of ADAMTS-1, -4, -5 and TIMP-3, 
were analysed, as well as the housekeeping gene GAPDH to normalise expression between 
different samples. Sequences were confirmed as unique by a BLAST search 
(www.ncbi.nlm.nih.gov/BLAST).  
 
Each primer pair generated a single product of the appropriate size when visualised by 
agarose gel electrophoresis, and by melt curve analysis following qRT-PCR. Primer pair 
efficiency was determined by plotting log cDNA dilution against cycle threshold (CT), the 
slope of which was -3.3 +/- 0.1 for each primer pair, indicating maximal efficiency. Relative 
mRNA levels of ADAMTS-1, -4, -5, and TIMP-3, were determined using the formula  2-∆CT 
where ∆CT = CT (target gene) – CT (GAPDH).  
 
Western blotting 
Western blot analyses of ADAMTS-1, -4 and -5 and TIMP-3 were carried out using rabbit 
polyclonal antibodies for C-terminal epitopes of ADAMTS-1, -4 and -5 (Triple Point 
Biologics, USA) and a monoclonal antibody for TIMP-3 (Oncogene, Germany). Protein 
concentrations were determined using the bicinchoninic acid assay [37]. 6µg of protein per 
well was separated by electrophoresis on 12% NuPAGE gels (Invitrogen, Paisley, UK) under 
reducing conditions. The proteins in the gel were electroblotted onto a nitrocellulose 
membrane (Hybond-C, Amersham, UK) at 150V for 1 hour, on ice. Blots were blocked for 2 
hours at ambient temperature with 5% non-fat milk in Tris-buffered saline containing 0.05% 
Tween 20 (Sigma, UK) (TBST). The blots were washed 3 x 10 min in TBST and the primary 
antibody was added  at 1: 5000 dilution or in the case of TIMP-3 blots, 1: 1000 in TBST 
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containing 5% non-fat milk.  The blots were incubated overnight at 4oC with gentle shaking 
and washed as described above, then incubated with goat anti-rabbit IgG horseradish 
peroxidase (HRP) conjugate (Sigma, UK), 1:80000 in TBST for the anti-ADAMTS and 
TIMP-3 antibodies, and rabbit anti-mouse IgG HRP conjugate (Dako, UK), 1:1000 in TBST 
containing 5% non-fat milk for 2 hours at ambient temperature with gentle shaking. The blots 
were washed 3 x 5 min in TBST followed by three washes in Tris-buffered saline for 5 min.  
Development of the blots was carried out using the ECL Plus chemiluminescence substrate 
(Amersham, UK). Images were captured using a UVP bioimaging system (Biorad, 
Hertfordshire, UK). Semi-quantitation of the bands was carried out by densitometry. Western 
blot experiments were repeated three times. 
 
Immunohistochemistry  
Immunohistochemistry was carried out on acetone-fixed cryostat sections (15µm) of spinal 
cord. For single staining, ADAMTS−4 was detected using the antibody against the C-terminal 
epitope of ADAMTS-4 (1:50) described above, followed by incubation with Alexa 488 
(green) goat anti-rabbit IgG (1:500) (Molecular Probes).  Dual immunofluorescence labelling 
was carried out using the ADAMTS-4 antibody followed by Alexa 568 (red) -conjugated goat 
anti-rabbit IgG (1:500) with detection of glial fibrillary acidic protein (GFAP) (astrocyte 
marker) (1:100) or a macrophage marker, ED-1 (1:50) (Serotec, UK) using  a primary 
monoclonal antibody followed by FITC-labelled (green) rabbit anti-mouse IgG (1:50).  Slides 
were examined using a Zeiss LSM 510 confocal microscope.  
 
Data Analysis 
Comparison of the expression levels of ADAMTSs and TIMP-3 between different groups was 
performed using the Mann-Whitney test.  P<0.05 was considered to be significant. 
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Results 
 
Rat spinal cord white matter, from all normal animals was found to express mRNA for 
ADAMTS-1, -4, -5 and TIMP-3 (Figure 1). ADAMTS-1 being the lowest expressed of the 
ADAMTSs.  ADAMTS-4 was the highest expressed gene amongst the control group and 
ADAMTS-5 demonstrated the most variable levels between naive animals (Figure 1). 
 
Although ADAMTS-1 was the lowest expressed gene tested, this was the only ADAMTS 
which showed a statistically significant increase in mRNA expression levels following 
induction of EAE, although this was only in the animals in the pre-disease group (Figure 2a). 
At the peak of disease and in recovery animals, the ADAMTS-1 levels were not significantly 
different from controls. In contrast, protein levels of ADAMTS-1 showed a decrease in the 
predominant form (64kDa) and in a 50kDa truncated form (assessed by western blotting and 
densitometry) (P<0.05), in all EAE animals compared to controls (Figure 3a and f). 
 
In contrast, ADAMTS-4 mRNA levels were significantly decreased in the group of rats at the 
peak of clinical symptoms compared to the control group and levels had returned to normal in 
the recovery group of animals (Figure 2b). Protein levels of ADAMTS-4 (65, 55, 50kDa 
forms) were also lower in EAE animals compared to control animals (Figure 3b and g), 
although the recovery group showed a slight (non-significant) increase in ADAMTS-4 
compared to the animals at peak of disease, whilst still being significantly lower than control 
animals. 
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ADAMTS-5 mRNA levels were not significantly different in any of the groups of animals 
(Figure 2c) although protein levels of ADAMTS-5 were significantly lower in recovery 
animals compared to controls, pre-disease and peak disease groups (Figure 3c and h). 
 
Levels of mRNA expression of TIMP-3 were significantly decreased in the animals at the 
peak of disease compared to the normal animal group (Figure 2d). In the recovery group of 
animals, TIMP-3 levels were not significantly different from the mRNA levels detected in 
normal control animals. The protein levels of TIMP-3 did not mirror the mRNA levels, with 
an increase in TIMP-3 detected as a 24kDa species in all EAE groups compared to the control 
animals (Figure 3d and i). An additional higher molecular weight species (48kDa) was 
detected in all samples. 
 
Immunohistochemical analysis of näive and EAE spinal cord demonstrated an overall 
decrease in the amount of ADAMTS-4 staining associated with astrocytes (Figure 4a-f). A 
greater amount of staining for ADAMTS-4 in an area of inflammation in diseased tissue was 
observed (Figure 4g-i). Some of the ADAMTS-4 staining in the inflamed area was 
colocalised to astrocytes although some was not. This ADAMTS-4 was subsequently 
colocalised with ED-1 positive infiltrating macrophages (Figure 4j-l). Not all ED-1 positive 
cells were colocalised with ADAMTS-4 suggesting that these cells may be the resident 
macrophages.  In both control and EAE tissue there was colocalisation of GFAP positive cells 
with ADAMTS-4 positive cells and this appeared to be strongest in the astrocyte processes 
(Figures 4m-o). There was also staining of the ECM, particularly in the diseased tissue. Only 
very weak staining was achieved using ADAMTS-1 and -5 antibodies with no differences in 
distribution between normal and EAE tissue (data not shown). 
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Discussion  
 
The brain ECM components are altered during injury and inflammation when the normal 
balance between proteases and their inhibitors is changed. Proteolytic activity in the CNS may 
lead to breakdown of the blood-brain barrier, or to loss of myelin, whereas an over-expression 
of protease inhibitors may cause fibrosis [38].   
 
Little is known about the role of ADAMTSs in CNS inflammation and injury. A small 
number of studies [20-23] have reported the presence of ADAMTSs in the CNS but few have 
quantitatively examined ADAMTS expression in diseased CNS.  
 
We have demonstrated the presence of ADAMTS-1, -4 and -5 in normal and EAE spinal cord 
and shown changes in expression of mRNA and protein levels during the course of EAE. 
ADAMTS-1 had the lowest level of expression of the ADAMTSs, although it was the only 
ADAMTS with increased mRNA levels in animals with EAE (pre-disease) compared to 
normal controls.  An increase in ADAMTS-1 mRNA has also been demonstrated by Sasaki et 
al [39], who found that ADAMTS-1 was expressed at very low levels by rat hypoglossal 
motor neurons but following nerve injury, mRNA levels were rapidly increased. In our study 
the increase in ADAMTS-1 mRNA in pre-disease animals was not mirrored by protein levels. 
The predominant ADAMTS-1 species of 64kDa and the 50kDa truncated species were 
decreased in pre-, peak and recovered EAE animals compared to controls. This may suggest 
that ADAMTS-1 itself is under attack from other proteases, such as MMPs, which are likely 
to be upregulated in an inflammatory condition [16]. 
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Our study revealed that ADAMTS-4 was the most highly expressed RNA of the ADAMTSs 
studied. It is likely to be important in CNS CSPG turnover and the reduction in its expression 
in EAE may decrease proteolytic degradation of CSPG and, depending on the degree of C-
terminal processing of ADAMTS-4, other substrates such as fibromodulin and decorin [40]. 
Although ADAMTS-4 expression was found to be reduced in EAE compared with naive 
tissue, immunohistochemical analysis of näive and EAE spinal cord also demonstrated a 
greater amount of staining for ADAMTS-4 in an area of inflammation.  There was, in both 
cases colocalisation with GFAP which demonstrated that some of the ADAMTS-4 was 
associated with astrocytes, possibly via interaction of cell surface proteins with the 
disintegrin-like region of ADAMTS-4, or through binding of the thrombospondin motif to 
cell-surface proteoglycans such as syndecans.  Some of the ADAMTS-4 immunoreactivity in 
the inflammatory cuff was colocalised with macrophages as well as astrocytes although not 
all macrophages were ADAMTS-4 positive. There was also some staining of the ECM, 
particularly in the diseased tissue, which may be mediated by the thrombospondin motif on 
the enzyme.  Such a store of sequestered enzyme may represent a pool of proteolytic activity 
in the remodelling matrix. Pericellular and ECM localisation has been observed previously for 
ADAMTS-5 in diseased synovium [41]. 
 
We have recently demonstrated that cytokines involved in CNS inflammation alter the 
processing of ADAMTS-4 in primary human astrocytes and astrocytoma cells (Cross et al, in 
preparation). Changes in the processing of the enzyme in vivo may depend on the cytokine 
microenvironment whereby an overall decrease in levels of ADAMTS-4 and changes in the 
processing of the enzyme, are likely to be important factors impacting upon the composition 
of the CNS ECM during EAE. A reduction in ADAMTS activity in EAE may lead to an 
increase in CSPG deposition and glial scarring creating an inhibitory environment for neurite 
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outgrowth and repair. It must also be noted that other metalloproteinases, such as MMP-3 
(stromelysin) are able to cleave CSPGs [42]. MMP-3 is expressed in the CNS and is also 
inhibited by TIMP-3 [16]. 
 
In the present study, TIMP-3 mRNA levels were significantly reduced in peak EAE compared 
to control animals, although TIMP-3 protein levels appeared to be increased in EAE. Toft-
Hansen et al, [43], also reported a decrease in TIMP-3 expression at the mRNA level EAE 
spinal cord in a mouse model. The increase in TIMP-3 protein could reflect an increase in 
translation of its mRNA transcript, or could be due to increased stability (longer half-life) of 
the protein. It was noticeable that the 24kDa form of TIMP-3 was only seen during and after 
the disease process and that a 48kDa species was seen throughout. TIMP-3 is known to be 
bound to the ECM  unlike TIMP-1 and TIMP-2 [44],[45] and the higher molecular weight 
species have been proposed to be stable complexes of TIMP-3 with  ECM ligands [46]. An 
alternative explanation is that the 48kDa species may be an as yet un-described brain specific 
dimer of TIMP-3. An increase in TIMP-3 protein levels in peak EAE indicates inhibition and 
control of metalloprotease activity during and after the peak of the inflammatory response. 
 
In conclusion, we have demonstrated changes in the expression levels of ADAMTSs and 
TIMP-3. These changes may be important in tissue damage during inflammation as well as 
tissue remodelling and repair. Due to the increasing number of known substrates for the 
ADAMTSs, changes in expression levels could be either beneficial or detrimental. A decrease 
in ADAMTSs, could lead to decreased degradation of CSPGs allowing accumulation of 
matrix proteins and formation of glial scars. The outcome of the response to the CNS 
inflammation will depend in part on the relative levels of the full-length and truncated forms 
of ADAMTSs and TIMP-3. 
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Figure legends  
Figure 1. Real-time PCR was carried out on spinal cord from normal animals to show relative 
levels (compared to GAPDH, calculated using the formula 2-∆CT where ∆CT is CT of target 
gene - CT of GAPDH) of ADAMTSs and TIMP3 in normal rat spinal cord. Data represents 
median (-) and relative levels compared to GAPDH for individual animals.  
 
Figure 2.  Real time PCR was carried out on spinal cord from control animals and those with 
EAE at different stages of disease progression. Data shows real time PCR results for 
ADAMTS-1 (a), ADAMTS-4 (b), ADAMTS-5 (c) and TIMP-3 (d). The median  value is 
shown as (-) and data are calculated as 2-∆CT where ∆CT is CT of target gene - CT of GAPDH 
(housekeeping gene). * indicates significant difference from control (P<0.05). 
 
Figure 3 Western blot analysis and densitometry for ADAMTS and TIMP-3 expression. 
Western blots of ADAMTS-1 (a), ADAMTS-4 (b), ADAMTS-5 (c) TIMP-3 (d) and β-actin 
loading control (e). Lanes: M = molecular weight marker, 1-2 normal, 3-4 pre-disease, 5-6 
peak disease, 7-8 recovered.  
Densitometry for ADAMTS-1 (f) ADAMTS-4 (g), ADAMTS-5 (h) and TIMP-3 (i). Each bar 
on the graph represents mean integrated optical density (IOD) +/- standard error of the mean 
of each group of animals (normal, pre-disease, peak disease and recovered) repeated 3 times. 
IOD values were pooled from all detected forms. * indicates significantly different from 
control (P<0.05). 
 
Figure 4  Immunohistochemistry on control (a-c) and EAE (d-o) tissue. Figures 4a, d, 
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g, j, and m show ADAMTS-4 staining. Figures 4b, e, h and n show GFAP staining. Figure 4k 
shows ED-1 staining. True colocalised pixels are represented as white in the merged images 
(Figures 4c, f, i, l and o).  Bar represents 50µM on all except for m, n and o where it 
represents 20µM.  
 
